Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agex Therapeutics Inc (NY: AGE )

0.6403 -0.0597 (-8.53%)
Streaming Delayed Price Updated: 10:50 AM EDT, Aug 11, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,688
Open 0.7140
Bid (Size) 0.6400 (31)
Ask (Size) 0.6500 (122)
Prev. Close 0.7000
Today's Range 0.6403 - 0.7140
52wk Range 0.5162 - 1.390
Shares Outstanding 37,943,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. 
Via Benzinga
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
From AgeX Therapeutics, Inc.
Via Business Wire

Performance

YTD
-32.60%
-32.60%
1 Month
-1.51%
-1.51%
3 Month
-9.27%
-9.27%
6 Month
-21.46%
-21.46%
1 Year
-50.75%
-50.75%

More News

Read More
AgeX Therapeutics Reports First Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
60 Biggest Movers From Yesterday
Via Benzinga
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
58 Biggest Movers From Yesterday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
61 Biggest Movers From Yesterday
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
18 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
40 Biggest Movers From Friday
Via Benzinga
Braeden Lichti: The Business of Anti-Aging and Rejuvenation Biotechnology
Via PRLog
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
From AgeX Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property Product Safety
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
From AgeX Therapeutics , Inc.
Via Business Wire
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
A Peek Into The Markets: US Stock Futures Down Following Friday's Rally
Via Benzinga
5 Stocks To Watch For July 26, 2021
Via Benzinga
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
From AgeX Therapeutics
Via Business Wire
58 Biggest Movers From Yesterday
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
21 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.